Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
featured
ENSURE-AF

ENSURE-AF

  • 62 views
  • 25 Mar, 2021
  • 1 location
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be

  • 0 views
  • 23 Jan, 2021
  • 16 locations
Hamburg Edoxaban for Anticoagulation in COVID-19 Study

Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate anticoagulation

  • 2 views
  • 26 Jan, 2021
  • 8 locations
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19

mediating inflammation. A direct factor X inhibitor, namely edoxaban can act as prophylactic measure to mitigate the risk of venous and arterial thrombotic complications. Colchicine is an

  • 0 views
  • 05 Aug, 2021
  • 11 locations
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease

This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis 50% on medical treatment or

artery disease
coronary artery bypass
angiography
stenosis
computed tomography angiography
  • 45 views
  • 27 Aug, 2021
  • 14 locations
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of

vascular disease
stroke
edoxaban
anticoagulants
atrial fibrillation
  • 0 views
  • 11 Feb, 2021
  • 1 location
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

A committee will judge the safety and effectiveness of edoxaban and the regular treatment (standard of care). All children in the study will receive free treatment. They will have a 2 in

primary prevention
heart failure
secondary prevention
thrombosis
  • 40 views
  • 26 Jan, 2021
  • 63 locations
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.

heparin
venous thromboembolism
edoxaban
vitamin k antagonist
heparin therapy
  • 0 views
  • 28 Jan, 2021
  • 170 locations
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein

venous thrombosis
edoxaban
clot
cancer
thrombosis
  • 9 views
  • 19 Sep, 2021
  • 1 location
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in non-valvular atrial fibrillation across Danish hospitals and cardiology clinics

edoxaban
apixaban
rivaroxaban
vitamin k antagonist
dabigatran
  • 35 views
  • 22 Jan, 2021
  • 25 locations